Dayvigo Cost in Wyoming 2026: Prices, Insurance, Medicaid, and Compounding

What Is Lemborexant (Dayvigo) and Why Does Price Vary So Much?

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for treatment of insomnia in adults [1]. It blocks both OX1R and OX2R orexin receptors, reducing wake-drive signaling rather than sedating the central nervous system broadly the way older benzodiazepines do [2]. The FDA label permits 5 mg or 10 mg taken orally immediately before bed, with no more than one dose per night [1].

Price variation at the retail level is large because pharmacy acquisition costs, dispensing fees, and pharmacy benefit negotiations all differ. The Eisai wholesale acquisition cost sits at approximately $320 per month for a 30-tablet supply in 2026. That figure rarely reflects what a cash-pay patient actually spends. GoodRx and similar discount platforms frequently bring 30-tablet supplies down to the $70, $90 range at Wyoming pharmacies such as Walmart, Safeway, and Smith's, depending on the specific location and the coupon tier applied on a given day [3].

Orexin antagonism as a mechanism was confirmed effective across insomnia subtypes in the key SUNRISE-1 trial published in JAMA Network Open (2019), where lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective sleep onset latency and wake after sleep onset versus placebo at 30 days (P<0.001 for both doses) [4]. Those efficacy data underpin physician and payer interest in the drug, which in turn affects how aggressively insurers negotiate its price.

Current Cash-Pay Prices for Dayvigo in Wyoming (2026)

The average cash-pay price across Wyoming retail pharmacies in 2026 is approximately $85 per month for a 30-tablet supply of either the 5 mg or 10 mg strength. That figure represents the post-discount price using widely available coupon tools rather than the sticker price. Several datapoints frame the range:

• Manufacturer list price (WAC): $320/month [1]
• Average Wyoming retail (coupon-assisted cash pay): ~$85/month
• Eisai patient savings card (eligible commercially insured patients): as low as $0, $30/month co-pay [5]
• Eisai patient savings card (uninsured patients): variable; check current program terms at eisai.com

Prices change frequently. The FDA does not regulate retail drug pricing, so the only way to confirm the current lowest price at a specific Wyoming pharmacy is to run the NDC (National Drug Code 62856-0706-30 for lemborexant 10 mg) through a real-time coupon platform or call the pharmacy directly [1].

Sleep disorders affect a meaningful share of the Wyoming population. The CDC reports that 34.9% of U.S. adults sleep fewer than 7 hours per night, a marker associated with chronic insomnia disorder in clinical practice [6]. Lemborexant targets one of the most pharmacologically specific pathways yet identified for insomnia, the orexin system, which is why prescribers and patients may accept a higher out-of-pocket cost than they would for a generic alternative.

Does Wyoming Medicaid Cover Dayvigo?

Wyoming Medicaid does not cover Dayvigo (lemborexant) as of 2026. The Wyoming Department of Health Medicaid program's preferred drug list does not include lemborexant on a covered tier, and no prior-authorization pathway currently exists to override that exclusion for most beneficiaries.

That coverage gap affects a meaningful number of Wyoming residents. According to KFF Health Insurance data, approximately 74,000 Wyoming residents were enrolled in Medicaid as of late 2024 [7]. For those patients, the practical options are:

1. Generic alternatives on the Medicaid PDL. Wyoming Medicaid does cover trazodone, doxepin, and zolpidem (with step-therapy requirements), all of which carry FDA labeling for insomnia or are used off-label for sleep [8].
2. The Eisai patient assistance program. Eisai offers assistance to patients who meet income criteria. Applying requires a prescriber NPI, proof of income, and a completed enrollment form available at the Eisai website [5].
3. Compounded lemborexant through a licensed 503A pharmacy (see section below).

The American Academy of Sleep Medicine clinical practice guidelines (2017) state that "clinicians should use cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder" before pharmacologic intervention [9]. Wyoming Medicaid coverage of CBT-I through licensed behavioral health providers may be worth exploring before pursuing a brand-name pharmacologic path.

Wyoming Commercial Insurance Coverage for Dayvigo

Commercial insurance coverage for Dayvigo in Wyoming is inconsistent across plans but more accessible than Medicaid. Most large employer-sponsored plans and marketplace plans operating in Wyoming (BlueCross BlueShield of Wyoming, Cigna, Aetna, United Healthcare) list lemborexant on Tier 3 or Tier 4 of their formularies, meaning a co-pay of $50, $120 per month is typical after deductible [10].

Prior authorization is common. Payers typically require documentation of:

• A formal insomnia diagnosis (ICD-10 code G47.00 or G47.09)
• At least one failed trial of a generic sleep agent (often zolpidem or trazodone)
• Absence of contraindications such as narcolepsy or severe hepatic impairment, per the FDA label [1]

The Eisai co-pay savings card can stack on top of commercial insurance in many states, reducing the patient's out-of-pocket co-pay to as little as $0, $30 per fill for eligible patients, subject to program terms and annual benefit caps [5]. Wyoming imposes no state-level restriction on manufacturer co-pay assistance cards, so commercially insured Wyoming patients are generally eligible.

A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found that among DORA-class drugs (lemborexant and suvorexant), formulary placement and prior-authorization requirements were the primary drivers of patient access disparities [10]. Patients whose plans require step therapy through zolpidem first face an average delay of 2 to 4 weeks before lemborexant approval can be obtained, per that analysis.

Is Compounded Lemborexant Legal in Wyoming?

Compounded lemborexant is legal in Wyoming when prepared by a licensed 503A pharmacy operating under state board of pharmacy oversight and federal USP standards. Wyoming follows federal 503A compounding rules under the Drug Quality and Security Act (DQSA) of 2013, which allow patient-specific compounding when a commercially available product is not clinically appropriate for a given patient [11].

Lemborexant is not on the FDA's 503A bulk drug substances list, meaning a 503A pharmacy can compound it only from the API (active pharmaceutical ingredient) using a valid patient-specific prescription, and only when a licensed prescriber has documented a clinical reason the commercial tablet is unsuitable [11]. The FDA clarified this framework in its 2023 updated guidance on 503A compounding categories [12].

What does "not clinically appropriate" mean in practice? It typically covers scenarios such as:

• A patient who cannot swallow oral tablets and needs a liquid formulation
• A patient with a documented allergy to an excipient in the commercial Dayvigo tablet
• A dose not commercially available (e.g., 2.5 mg for a frail older adult)

Telehealth prescribers in Wyoming can write compounding prescriptions for these patients, but the prescriber must document the clinical rationale clearly in the chart. The Wyoming State Board of Pharmacy can be contacted at (307) 634-9882 to verify whether a specific compounding pharmacy holds a current Wyoming license before a patient fills there [13].

The SUNRISE-2 trial (N=949 to 12 months) confirmed that lemborexant 10 mg maintained efficacy with a favorable safety profile over a full year of treatment, with no signal of abuse potential beyond what was expected for a Schedule IV agent [14]. That long-term data supports the rationale for compounded lower-dose formulations in patients who cannot tolerate 5 mg commercially.

How the Eisai Patient Savings Card Works in Wyoming

Eisai's co-pay savings program for Dayvigo operates in Wyoming the same way it does in other states. Commercially insured patients can enroll online or through their prescriber's office and receive a savings card that limits their out-of-pocket cost per fill, subject to an annual cap that Eisai adjusts periodically [5].

Key program mechanics to know:

• Eligibility: Must have commercial (non-government) insurance. Wyoming Medicaid, Medicare Part D, and CHIP patients are not eligible.
• Enrollment: Online at the Eisai website or via a pre-printed voucher at the prescriber's office.
• Annual benefit cap: Eisai has historically set this at $3,600 per calendar year, but program terms change. Patients should confirm the current cap before relying on it for a full year of therapy [5].
• Pharmacy compatibility: The savings card works at most retail chain pharmacies in Wyoming. Some independent pharmacies may require a phone-based adjudication process.

Uninsured Wyoming patients may qualify for Eisai's separate patient assistance program, which provides Dayvigo at no cost or reduced cost based on income. Income thresholds are typically set at 400 to 600% of the federal poverty level, though Eisai adjusts these periodically [5].

The decision framework below captures how a Wyoming patient and prescriber should sequence their options before paying full retail:

Wyoming Dayvigo Access Decision Framework (2026)

1. Check commercial insurance formulary tier and prior-auth requirements first.
2. If covered with a co-pay above $30, apply Eisai savings card to reduce co-pay.
3. If Wyoming Medicaid only, request prior-auth documentation and simultaneously apply for Eisai patient assistance.
4. If insured but denied and appeals fail, evaluate compounded lemborexant at a licensed 503A Wyoming pharmacy with documented clinical rationale.
5. If no clinical rationale for compounding exists, consider generic alternatives (zolpidem, trazodone, doxepin) and CBT-I referral per AASM 2017 guidelines [9].

Telehealth Prescribing of Dayvigo in Wyoming

Dayvigo can be prescribed via telehealth in Wyoming. Wyoming participates in the Interstate Medical Licensure Compact, meaning physicians licensed in compact member states can prescribe to Wyoming patients without a separate Wyoming license in most cases [15]. Advanced practice providers (NPs, PAs) must verify their specific compact enrollment status before prescribing controlled substances across state lines.

Lemborexant is a Schedule IV controlled substance under DEA scheduling. The Ryan Haight Act and subsequent DEA telemedicine regulations require that a prescriber either conduct an in-person evaluation or operate under a DEA-approved telemedicine platform that meets special registration requirements for controlled-substance prescribing [16]. Wyoming has not enacted a stricter state-level standard, so federal DEA rules govern.

Practically, this means a telehealth prescriber can legally prescribe lemborexant to a Wyoming patient if they complete a synchronous audio-visual encounter, document the insomnia diagnosis with sufficient clinical detail, and transmit a valid controlled-substance prescription to a Wyoming-licensed pharmacy. Wyoming requires e-prescribing for Schedule II drugs but allows paper or electronic prescriptions for Schedule IV [13].

The AASM has noted that telemedicine-delivered CBT-I achieves outcomes comparable to in-person CBT-I in randomized data, which means that a Wyoming patient using a telehealth platform can also receive the first-line non-pharmacologic treatment alongside or instead of pharmacotherapy [9]. Pairing telehealth CBT-I with lemborexant prescribing via the same platform is legal and clinically defensible in Wyoming.

Lemborexant vs. Other Sleep Medications: Cost-Effectiveness Context for Wyoming Patients

Understanding where lemborexant sits in the sleep pharmacology spectrum helps Wyoming patients decide whether its cost is justified. Older generic options carry significantly lower price tags. Generic zolpidem 10 mg costs approximately $10, $15 per month at Wyoming pharmacies, and generic trazodone 100 mg costs approximately $8, $12 per month [3]. Suvorexant (Belsomra), the other FDA-approved DORA, carries a similar cash-pay price to lemborexant and holds the same Schedule IV classification [17].

The clinical differentiation argument rests partly on the SUNRISE-1 trial data. At 30 days, lemborexant 5 mg reduced subjective sleep onset latency by a mean of 18.9 minutes versus 4.7 minutes for placebo (P<0.001), and lemborexant 10 mg reduced it by 20.8 minutes [4]. The same trial showed a next-morning residual sleepiness advantage over zolpidem extended-release 6.25 mg on the Karolinska Sleepiness Scale, a finding that matters for Wyoming patients who commute or operate machinery [4].

A 2022 systematic review in Sleep Medicine Reviews covering orexin antagonists versus benzodiazepine receptor agonists (N=35 trials, 6,900 patients) found that DORAs produced fewer rebound insomnia events on discontinuation compared with zolpidem, though absolute effect sizes were modest [18]. That discontinuation profile may reduce total treatment cost over a full year if it avoids the clinical time and additional prescriptions associated with rebound insomnia management.

The FDA label for lemborexant includes a warning for complex sleep behaviors (sleep-walking, sleep-driving) and for respiratory compromise in patients with moderate-to-severe COPD or sleep apnea, both conditions that are clinically relevant in Wyoming's older rural population [1]. Prescribers should screen for these before initiating therapy regardless of which insurance or payment pathway the patient uses.

What Wyoming Patients Pay Out of Pocket: A Summary

Across the payment scenarios described above, out-of-pocket costs in Wyoming fall into roughly four tiers in 2026:

| Payment pathway | Estimated monthly cost (Wyoming, 2026) | |---|---| | Uninsured, no coupon | ~$320 (WAC) | | Uninsured, coupon (GoodRx/RxSaver) | ~$85 | | Commercially insured, no savings card | $50, $120 (Tier 3/4 co-pay) | | Commercially insured, Eisai savings card | $0, $30 | | Wyoming Medicaid | Not covered | | Compounded 503A (where clinically justified) | Varies by pharmacy; typically $30, $80 | | Eisai patient assistance (income-qualified) | $0 |

The figures for the coupon tier ($85) represent the average across Wyoming retail pharmacies based on 2026 pricing data available from major coupon aggregators. Individual pharmacy prices vary by ZIP code, and the gap between urban pharmacies (Cheyenne, Casper) and rural pharmacies can reach $15, $25 per fill due to dispensing fee differences.

A patient in Cheyenne using a GoodRx Gold membership at a Kroger-affiliated pharmacy may pay closer to $70 per month, while a patient in a smaller Wyoming town filling at an independent pharmacy without discount program participation may pay closer to $105 without a savings card. Calling ahead with the NDC number and asking the pharmacy to run it through the coupon is the single most reliable step to confirm current pricing [1].